Ziprasidone Mesylate has 20 known drug interactions based on U.S. FDA drug labeling data. Of these, 2 are contraindicated combinations that should be avoided entirely. 6 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Drugs That Prolong Qtc Interval, Drugs That Prolong The Qt Interval, Amphetamine. Patients taking Ziprasidone Mesylate should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 20
- Contraindicated
- 2
- Major
- 6
- Moderate
- 6
- Minor
- 3
Contraindicated (2)
- Ziprasidone Mesylate + Drugs That Prolong Qtc Interval— Ziprasidone should not be used in combination with other drugs that have demonstrated QT prolongation due to risk of ser…
- Ziprasidone Mesylate + Drugs That Prolong The Qt Interval— Ziprasidone should not be used in combination with other drugs that have demonstrated QT prolongation due to risk of ser…
Major (6)
- Ziprasidone Mesylate + Amphetamine— Risk of serotonin syndrome with concomitant serotonergic therapy including amphetamines.
- Ziprasidone Mesylate + Buspirone— Risk of serotonin syndrome with concomitant serotonergic therapy including buspirone.
- Ziprasidone Mesylate + Lithium— Risk of serotonin syndrome with concomitant serotonergic therapy including lithium.
- Ziprasidone Mesylate + St. John'S Wort— Risk of serotonin syndrome with concomitant serotonergic therapy including St. John's Wort.
- Ziprasidone Mesylate + Triptans— Risk of serotonin syndrome with concomitant serotonergic therapy including triptans.
- Ziprasidone Mesylate + Tryptophan— Risk of serotonin syndrome with concomitant serotonergic therapy including tryptophan.
Moderate (6)
- Ziprasidone Mesylate + Acidifying Agents— Ziprasidone may enhance the hypotensive effects of antihypertensive agents due to its potential for inducing hypotension…
- Ziprasidone Mesylate + Carbamazepine— Carbamazepine induces CYP3A4, decreasing ziprasidone AUC by approximately 35%, with potentially greater effects at highe…
- Ziprasidone Mesylate + Centrally Acting Drugs— Caution should be used when ziprasidone is taken in combination with other centrally acting drugs due to its CNS effects…
- Ziprasidone Mesylate + Dopamine Agonists— Ziprasidone may antagonize the effects of dopamine agonists.
- Ziprasidone Mesylate + Ketoconazole— Ketoconazole, a potent CYP3A4 inhibitor, increases ziprasidone AUC and Cmax by approximately 35-40%.
- Ziprasidone Mesylate + Levodopa— Ziprasidone may antagonize the effects of levodopa.
Minor (3)
- Ziprasidone Mesylate + Antacids Containing Calcium— Co-administration of Maalox did not affect ziprasidone pharmacokinetics.
- Ziprasidone Mesylate + Cimetidine— Cimetidine 800 mg daily for 2 days did not affect ziprasidone pharmacokinetics.
- Ziprasidone Mesylate + Maalox— Co-administration of Maalox did not affect ziprasidone pharmacokinetics.